



www.genfit.com

GENFIT: IMPLEMENTATION OF THE FOURTH INSTALLMENT (€1 M) OF THE RESERVED CONVERTIBLE BOND LOAN AGREEMENT OF €8 M

- **At GENFIT's initiative, implementation of one of the 7 notes redeemable for bonds convertible into shares (BEOCA2012), giving access to a fourth €1 M convertible bond loan.**
- **55 of the 100 OCA2012-2 bonds resulting from this exercise have already been converted into shares by the Bondholder.**

Lille (France), Boston (Massachusetts, United States), February 14, 2013 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces that it has requested the implementation of the fourth installment of €1 M of the €8 M bond loan agreement, convertible into ordinary Company shares, signed on December 20th, 2012, as well as the conversion into shares of 55 of the 100 bonds of this fourth installment, in keeping with the 1st and 2nd resolutions of the Extraordinary Shareholders' Meeting of December 18th, 2012 ("the Assembly").

In keeping with these resolutions and with the convertible loan contract signed with the investment company Yorkville Advisors LLC acting for and on behalf of YA Global Master SPV Ltd ("the Bondholder"), GENFIT's Management Board, by its decision of February 12th, 2013, decided to authorize the Bondholder to implement the third of the 7 notes redeemable for bonds convertible into shares ("BEOCA2012"), giving access to 100 new OCA2012-2 bonds, convertible into shares under the same conditions as the first such bonds.

In keeping with the 1st and 2nd resolutions of the Assembly and with the convertible loan contract, the Bondholder made one conversion request on February 12th, 2013, of 55 OCA2012-2 bonds.

The conversion of the 55 OCA2012-2 bonds into 107,993 new shares was performed at a conversion rate of €5.09, issue premium included, equivalent to 95% of the arithmetic mean of the volume-weighted average GENFIT share price for the five (5) trading days (February 05-11, 2013) prior to the conversion request.

As a result of this conversion:

- The social capital of GENFIT has increased from €4,204,980.75 to €4,231,979;
- The number of shares representing the social capital of GENFIT has increased by 107,993, from 16,819,923 to 16,927,916 shares;
- The amount of the fourth installment of the bond loan agreement that remains to be converted is €450,000.

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases...). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in

partnership with leading pharmaceutical companies, including Sanofi, to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase IIb.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 80 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Contacts:

GENFIT

Jean-François Mouney – CEO & Chairman of the Management Board
Ph. +333 2016 4000

MILESTONES – Press Relations

Bruno Arabian
Ph. +331 7544 8740 / +336 8788 4726 – barabian@milestones.fr